Community Outreach and Engagement
| |
Let's Celebrate Women's Health
Saturday, May 15, 11:00am - noon CDT
Speaker:
Cynthia D. Jackson, PhD., Matthew Walker Comprehensive Health Center
| |
|
Let's Talk about Gynecologic Cancers
Thursday, May 20, 7:00pm - 8:00pm CDT
Ladies, let's take a moment to focus on our wellness by learning about the five main types of cancer that affect the woman's reproductive organs.
La detección temprana de los canceres ginecológicos
Jueves, Mayo 6, 7:00-8:00pm CDT
¡Señoras, dediquemos un momento para pensar en nuestra salud y bienestar! Las mujeres debemos cuidarnos para continuar progresando y apoyando a nuestras familias, amigos y comunidades.
Invitada a Presentar:
Luz Salazar Luz Salazar MSN, APN, FNP-C
| |
LGBTQ Cancer Care Survey
The Vanderbilt-Ingram Cancer Center is working to comprehensively serve the LGBTQ community. We would like to invite you to complete the LGBTQ Cancer Care Survey so that we can better understand your interest in (a) cancer prevention and early detection/screening and (b) educational and support resources for those individuals who have been impacted by cancer.
By sharing your input, you will assist us with ensuring our educational and support resources are more accessible and welcoming to the LGBTQ community.
Please fill out the brief LGBTQ Cancer Care Survey by visiting this link.
Thank you in advance for your participation!
| |
Patient and Family-Centered Care
| |
CAR T-Cell Therapy - Is it for You?
Wednesday, May 12, 6:00pm-7:00pm CDT
Join LLS for an overview of the patient journey from consultation for CAR T-cell therapy to follow up after treatment.
Speaker:
Brittney Baer, BSN, RN
Vanderbilt-Ingram Cancer Center
This program will guide patients wanting to educate themselves about the entire CAR T-cell therapy process. The presentation will focus on introducing this therapy earlier in the patient's treatment course.
Contact:
Tracy Moore, Patient & Community Outreach Manager, LLS
tracy.moore@LLS.org | 615-258-5491
| |
LGBTQ+ Individuals and Comprehensive Cancer Care
Tuesday, May 18, 11:00am - 12:00pm CDT
The Tennessee Cancer Coalition will be hosting a dynamic training opportunity led by the National LGBT Cancer Network introducing participants to LGBTQ+:
- Key concepts & terminology
- Electronic health records & data collection
- Health disparities
| |
Development and Fundraising
| |
Wilhagans Troubleshoot Golf Tournament
Monday, May 31, 2021 | Hermitage Golf Course
Join us for a day of golf, lunch, and silent auctions benefiting innovative cancer research at Vanderbilt-Ingram Cancer Center. This charity golf tournament has been taking place since 2012, in memory of Marie Bagsby, Wilhagan’s General Manager. If interested in participating, please email Casey Holden at casey.n.holden@vumc.org for more information.
| |
A Randomized, Placebo-Controlled Trial of Ifetroban, A Thromboxane A2 Receptor Antagonist, in Patients with Malignant Solid Tumors at High Risk of Metastatic Recurrence
Clinical Research Impact on our Community
- VICC is located in a region with some of the highest cancer death rates in the US.
- The most common cancer types in this includes lung, breast, prostate, and colorectal cancers.
- These types of cancers can spread from the primary tumor site to other parts of the body (metastatic cancer).
- Ifetroban, a drug that has been used in diseases other than cancer, may be able to interfere with the tumor’s ability to spread to other parts of the body which could prevent cancer recurrence and potential death.
- Ifetroban is being used in this clinical trial for patients with any cancer in a solid organ (such as lung, breast prostate and colorectal) that has at least a 50% risk of recurrence within 3 years of diagnosis.
PATIENT SUMMARY:
We believe that ifetroban may be able to help many patients with several different types of cancers at high risk for recurrence. Ifetroban has the potential to interfere with the tumor’s ability to spread, through the bloodstream, from the primary tumor to other parts of the body (metastatic process). That, in turn, could prevent cancer recurrence and consequent death. Ifetroban has already been shown to be very safe in many patients who have participated in clinical trials for cardiovascular and other diseases, and has a similar side effect profile to drugs that affect platelet function, such as aspirin. Patients with any type of solid tumor that have high risk of having their cancer come back can participate once all treatments normally prescribed for your cancer have been completed. Half of the participants will take one pill of ifetroban once daily for 1 year, the other half will take a placebo (i.e. a pill that looks exactly like ifetroban but only has a little sugar in it) once daily for the same amount of time. We will collect 1 tablespoon of blood every 3 months at your normal clinic visits during your participation in the trial. Once the year of treatment ends, information will be collected on cancer status (i.e. if the cancer came back or not) for the next 2 years. With this research, we are hoping to have a simple, safe and effective treatment to protect patients at high risk from having a recurrence of their cancer.
| |
PROVIDER SUMMARY:
Multiple independent, lines of evidence suggest ifetroban, a thromoboxane A2 receptor (gene:TBXA2R) antagonist that has already completed phase I testing and is currently in phase II for various non-oncology indications, could be repurposed to prevent and/or delay metastasis in multiple solid tumors: 1) our phenome-wide association study (PheWAS) uncovered a novel association between a TBXA2R variant and increased metastasis; 2) meta-analyses of clinical datasets show that increased TBXA2R expression correlates with poor survival in breast, lung, and gastric cancers; 3) published data implicate TBXA2R signaling in cancer metastasis; and 4) preclinical data (generated in support of this proposal) demonstrate that ifetroban inhibits metastasis in multiple, well-established murine models. In order to take the critical next step in translating these findings into the clinic, we are conducting a feasibility trial to evaluate the safety, tolerability and efficacy of ifetroban for prevention of metastatic recurrence across a number of aggressive, solid tumors. Patients with any solid tumor, stages I-III, that are deemed by their treating physician to have more than 50% chance of recurrence within the first 3 years of their diagnosis are eligible to participate. Within 3 months of completion of all of their (neo)adjuvant locoregional (i.e. surgery, RT, etc.) and systemic treatment (i.e. chemotherapy, biological agents, immunotherapy, etc.), patients are randomized to receive once daily oral ifetroban (250 mg) or placebo for 12 months. Clinic visits, CBC/diff, coags and PLT activation studies are conducted every 3 months throughout the treatment portion of the trial. Once therapy completed, patients’ clinical data will be followed for an additional 24 months to assess for metastatic recurrence.
| |
Community-Engaged Research
| |
Working towards improving awareness and care for those inherited cancer predisposition
Few individuals who may be at risk for inherited cancer realize that their personal or family history is enough to consider genetic testing. Even for those who have genetic testing that reveals they have inherited cancer, many do not get the recommended care to prevent future cancer or diagnose cancer early. There is also a gap in spreading this information to family members who could also benefit. To address these challenges, the Vanderbilt-Ingram Cancer Center (VICC) team and collaborators at University of South Florida (USF) recently launched the IMPACT (IMProving care After Inherited Cancer Testing) Study, which is a clinical trial to test strategies to improve both cancer risk management and family sharing practices among individuals with inherited cancer gene mutations. Our prior research has suggested that those with inherited cancer risk do not get the maximum benefit from having this information, (1, 2, 3) which is even more pronounced among Blacks and those who are socioeconomically disadvantaged.(4) If you are someone with a mutation in an inherited cancer risk gene with or without cancer, you may be eligible to participate in this trial and can learn more about it at: https://inheritedcancer.net/impact-study or look us up on the clinicaltrials.gov website: https://clinicaltrials.gov/ct2/show/NCT04763915.
To more broadly spread awareness and knowledge about inherited cancer, we have hosted our Inherited Cancer Registry (ICARE) Initiative, through which we strive to end the cycle of inherited cancer through research, education and engagement. We have partnerships across the country with providers who refer their patients to participate in our study. ICARE participants receive regular updates about new information that may be relevant to their care through newsletters and various social media platforms. To date, we have over 4000 participants in ICARE who either found out about us on our website or were referred to us by over 200 healthcare providers. Participation does not involve any travel to Vanderbilt and can all be done online from any location. To learn more about these efforts, please visit http://inheritedcancer.net or look us up on the clinicaltrials.gov website: https://clinicaltrials.gov/ct2/show/NCT03231891. To stay updated about inherited cancer, we invite you to follow us on Facebook, Twitter, and Instagram @inheritedcancer or on LinkedIn at: https://www.linkedin.com/company/inherited-cancer-registry/.
(1)Dean, et al. Patient Educ Couns. 2021 Jan. PMID: 33455826. (2)Cragun, et al. J Genet Couns. 2020 Nov. PMID: 33174380. (3)Cragun, et al. Breast Cancer Res Treat. 2020 Jul. PMID: 32445176. (4)Cragun, et al. Cancer, 2017 Feb. PMID: 28182268.
| |
Connect with Us!
Facebook: @VanderbiltIngram
Twitter: @VUMC_Cancer
Instagram: @vumc_cancer
VICC.org
| |
|
|
|
